Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined with camrelizumab in patients with locally advanced nasopharyngeal carcinoma.

Trial Details

NCT ID
NCT06811844
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Xiamen University
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • Two-cycle induction chemotherapy + immunotherapy
  • Three-cycle induction chemotherapy + immunotherapy
Locations (sample)
  • Xiamen, Fujian, China|24.47979,118.08187
  • Zhangzhou, Fujian, China|24.51333,117.65556
  • Haikou, Hainan, China|20.03421,110.34651

Key Eligibility Criteria

  • Age: 18-65 years old;
  • Pathologically (including histology or cytology) confirmed nasopharyngeal carcinoma patients, with clinical staging T1-4N2-3M0 (according to the UI…
  • No prior systemic treatment (surgery, radiotherapy, chemotherapy, etc.);
  • At least one measurable lesion on imaging (as per RECIST criteria version 1.1);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →